1055027-48-9

Basic information

• Product Name: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-
• Synonyms: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-;(1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-iMidazol-4-yl)butane-1,2,3,4-tetraol;(1R,2S,3R)-1-(2-(Isoxazol-3-yl)-1H-imidazol-5-yl)butane-1,2,3,4-tetraol
• CAS NO: 1055027-48-9
• Molecular Formula: C₁₀H₁₃N₃O₅
• Molecular Weight: 255.22732
• Mol File: 1055027-48-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-(1055027-48-9)
• EPA Substance Registry System: 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-iMidazol-5-yl]-, (1R,2S,3R)-(1055027-48-9)

Safety Data

• Hazardous Substances Data: 1055027-48-9(Hazardous Substances Data)

Usage

General Description

1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-imidazol-5-yl]-, (1R,2S,3R)- is a chemical compound with a complex structure. It is a stereochemically defined organic compound that contains butanetetrol, isoxazole, and imidazole moieties. The designation (1R,2S,3R) indicates the specific stereochemistry of the compound. 1,2,3,4-Butanetetrol, 1-[2-(3-isoxazolyl)-1H-imidazol-5-yl]-, (1R,2S,3R)- may have potential applications in the pharmaceutical or chemical industries, but further research and testing would be necessary to determine its specific properties and uses.

Upstream product

• 94944-70-4 (1'R,2'S,3'R)-2-acetyl-4⁽⁵⁾-(1',2',3',4'-tetrahydroxy-1'-butyl)imidazole 

Relevant articles and documents

Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: Discovery of (E)-1-(4-((1 R,2 S,3 R)-1,2,3,4-tetrahydroxybutyl)-1 H -imidazol-2-yl)ethanone oxime (LX2931) and (1 R,2 S,3 R)-1-(2-(Isoxazol-3-yl)-1 H -imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)

Sphingosine 1-phosphate lyase (S1PL) has been characterized as a novel target for the treatment of autoimmune disorders using genetic and pharmacological methods. Medicinal chemistry efforts targeting S1PL by direct in vivo evaluation of synthetic analogues of 2-acetyl-4(5)-(1(R),2(S),3(R),4- tetrahydroxybutyl)-imidazole (THI, 1) led to the discovery of 2 (LX2931) and 4 (LX2932). The immunological phenotypes observed in S1PL deficient mice were recapitulated by oral administration of 2 or 4. Oral dosing of 2 or 4 yielded a dose-dependent decrease in circulating lymphocyte numbers in multiple species and showed a therapeutic effect in rodent models of rheumatoid arthritis (RA). Phase I clinical trials indicated that 2, the first clinically studied inhibitor of S1PL, produced a dose-dependent and reversible reduction of circulating lymphocytes and was well tolerated at dose levels of up to 180 mg daily. Phase II evaluation of 2 in patients with active rheumatoid arthritis is currently underway.